Life Expectancy Project, 1439 17th Avenue San Francisco, CA 94122, USA.
Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales, Heath Park, Cardiff, United Kingdom; Helen Durham Centre for Neuroinflammatory Disease, Department of Neurology, University Hospital of Wales, Heath Park, Cardiff, United Kingdom.
Mult Scler Relat Disord. 2022 Dec;68:104219. doi: 10.1016/j.msard.2022.104219. Epub 2022 Oct 5.
The median survival time of newly-diagnosed MS patients without severe disabilities is approximately 30-35 years. The prognosis after the onset of severe disability has not been reported. Based on Harding et al.'s 2018 study of the Southeast Wales MS registry, we calculated life expectancies according to the Expanded Disability Status Scale (EDSS). Upon loss of independent ambulation (EDSS 6-6.5; mean age 51.2) life expectancy was 13.3 additional years. At EDSS 9-9.5 (mean age 70.8) life expectancy was 1.1 additional years. These figures provide an empirical basis for discussions of advanced MS care planning.
新诊断为 MS 且无严重残疾的患者的中位生存时间约为 30-35 年。严重残疾发病后的预后尚未报道。根据 Harding 等人 2018 年对东南威尔士 MS 登记处的研究，我们根据扩展残疾状况量表 (EDSS) 计算了预期寿命。丧失独立行走能力（EDSS 6-6.5；平均年龄 51.2）后，预期寿命增加 13.3 年。EDSS 9-9.5（平均年龄 70.8）时，预期寿命增加 1.1 年。这些数据为探讨晚期 MS 护理计划提供了经验依据。
